Abstracts Archive - Page 1811 of 2425 - ACR Meeting Abstracts

Abstract Number: 1830 • 2015 ACR/ARHP Annual Meeting
Periodontal Disease in Lupus Erythematosus and Cardiovascular Risk Factors
Maria Cecilia Goizueta¹, Luciana Gonzalez Lucero¹, Maria Constanza Bertolaccini², Ramiro Maldonado¹, Raul Sueldo¹, Raul Nicolas Martinez¹, María Silvia Yacuzzi¹, Maximiliano Machado Escobar¹, Mirta Santana¹, Jose Rodriguez Skegro¹, Eugenia fatima del Valle Reynoso¹, Patricia Morales¹, Liliana Galindo¹, Veronica Bellomio¹ and Eleonora Lucero¹, ¹Hospital Angel Cruz Padilla, Tucumán, Argentina, ²Rheumatology, Hospital Angel Cruz Padilla, Tucumán, Argentina
Background/Purpose: The aim of this study was to determine the prevalence of periodontal disease (POD) in patients with Systemic Lupus Erythematosus (SLE) and its relationship with…
Abstract Number: 1831 • 2015 ACR/ARHP Annual Meeting
Initial Risk Factor Profile and Long-Term Cardiovascular Outcome in Women with Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su², Olga Ace³, Arthy Sabapathy³, Anne MacKinnon³ and Murray Urowitz^4,5, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: We previously reported the influence of traditional and disease-related risk factors on the development of cardiovascular disease (CVD) in patients with systemic lupus erythematosus…
Abstract Number: 1832 • 2015 ACR/ARHP Annual Meeting
Recurrence-Rate of Thrombotic Events in SLE Patients Negative for Antiphospholipid Antibodies
Mohammed Attar¹, Jiandong Su², Stacey E. Morrison³, Samar Alharbi⁴, Khawla Al-Ghanim⁵, Dafna Gladman², Murray Urowitz^6,7 and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, TWH, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Thrombotic events (TE) are common in patients with SLE. Antiphospholipid antibodies (aPL) are a risk factor for incident and recurrent TE; therefore these patients…
Abstract Number: 1833 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis
Maeve Gamble¹ and Janet E. Pope², ¹Medicine, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Osteoporosis (OP) and avascular necrosis (AVN) are well-recognized musculoskeletal complications of systemic lupus erythematosus (SLE) and cause morbidity. Steroid therapy and the underlying disease…
Abstract Number: 1834 • 2015 ACR/ARHP Annual Meeting
Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?
Marco González-Contreras¹, Javier Merayo-Chalico¹, Rigoberto Ortíz-Hernández², Diana Gómez-Martín² and Jorge Alcocer-Varela², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: In patients with systemic lupus erythematosus (SLE), persistent joint activity and treatment with glucocorticoids are associated with musculoskeletal complications, including hip osteonecrosis. About 30%…
Abstract Number: 1835 • 2015 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement
Arielle Fein¹, Caroline Figgie¹, Taylor Dodds², Joshua Wright-Chisem³, Michael Parks⁴, Lisa Mandl⁵, Edwin Su⁶, Jane E. Salmon^5,7, David J. Mayman⁴, Yuo-Yu Lee⁸, Mark P. Figgie² and Susan M. Goodman⁷, ¹Research, Hospital for Special Surgery, New York, NY, ²Orthopaedics, Hospital for Special Surgery, New York, NY, ³University of Illinois at Chicago College of Medicine, Chicago, IL, ⁴Orthopedics, Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶Orthopedic Surgery, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY
Background/Purpose: More Systemic Lupus Erythematosus (SLE) patients are undergoing total knee arthroplasty (TKA) with equivalent benefits to osteoarthritis (OA) patients. While post-surgical adverse events (AEs)…
Abstract Number: 1836 • 2015 ACR/ARHP Annual Meeting
Standardized Incidence Ratio (SIR), Time Trend and Risk Factors of Avascular Bone Necrosis (AVN) in Patients with Systemic Lupus Erythematosus (SLE)
Sau Mei Tse¹, Chi Chiu Mok¹, Kar Li Chan¹ and Ling Yin Ho², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To study the standardized incidence ratio (SIR), time trend and risk factors of AVN in patients with SLE. Methods: The records of all patients…
Abstract Number: 1837 • 2015 ACR/ARHP Annual Meeting
Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up Study
Matteo Piga¹, Alessandra Gabba¹, Mattia Congia¹, Fabiana Figus¹, Alberto Floris^1,2, Alberto Cauli¹ and Alessandro Mathieu¹, ¹University of Cagliari, Cagliari, Italy, ²University of Oxford, Oxford, United Kingdom
Background/Purpose: SLE patients develop non-deforming non-erosive (NDNE) arthritis in 70-80%, but 5-15% of cases progresses into Jaccoud's arthropathy (JA) a non-erosive deforming arthritis. This study…
Abstract Number: 1838 • 2015 ACR/ARHP Annual Meeting
Joint Ultrasonography May be Useful to Assess Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: A Prospective Multicenter Study
Carine Salliot¹, Emmanuelle Dernis Labous², Aleth Perdriger³, Jean David Albert⁴, Amelie Denis⁵, Saloua Mammou⁶, Isabelle Griffoul⁷, Benoit Le Goff⁸, Sandrine Jousse-Joulin⁹, Christophe Richez¹⁰, Nicolas Poursac¹⁰, Mohamed Hamidou¹¹, Virginie Martaille¹², Antoine Valery¹³ and Emilie Ducourau¹⁴, ¹Rheumatology, CHR Orleans, Orléans, France, ²Réseau Hôpital et Ville en Rhumatologie (RHEVER) Network, Paris, France, ³Service de Rhumatologie, CHU de Rennes, Rennes, France, ⁴Rheumatology Unit, Rennes, France, ⁵Rheumatology, CH Le Mans, Le Mans, France, ⁶Rheumatology, CHU Tours, Tours, France, ⁷Rheumatology, CHU TOURS, Tours, France, ⁸Rheumatology, Nantes University Hospital, Nantes, France, ⁹Rheumatology, CHu La cavle Blanche, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹²Rheumatology, CHR Orléans, Orleans, France, ¹³Statistics, CHR Orleans, Orleans, France, ¹⁴Rheumatology, CHR Orleans, Orleans, France
Background/Purpose: Arthritis is a current manifestation of SLE and participates to the SLEDAI composite score calculation (0 to 105). Ultrasonography (US) is a validated and…
Abstract Number: 1839 • 2015 ACR/ARHP Annual Meeting
Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial Completion
J. Patricia Dhar^1,2, Lynnette Essenmacher³, Renee Dhar⁴, Ardella Magee⁵, Joel Ager⁶ and Robert Sokol⁷, ¹Internal Medicine, Wayne State University, Detroit, MI, ²Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, ³Wayne State University School of Medicine, Detroit, MI, ⁴CMED medical student, Central Michigan University College of Medicine, Mt. Pleasant, MI, ⁵Clinical and Translational Research Center, Wayne State University, Detroit, MI, ⁶Family Medicine, Wayne State University School of Medicine, Detroit, MI, ⁷Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI
Background/Purpose: Women with SLE are at increased risk for HPV-related cervical disease. The qHPV vaccine immunizes and is protective against HPV types that cause the…
Abstract Number: 1840 • 2015 ACR/ARHP Annual Meeting
How Good a Job Are We Rheumatologists Doing in Screening for Hepatitis B and C before Immuno-Suppressive/s Initiation in SLE?
Chandrahasa Annem¹, Joel A. Block² and Meenakshi Jolly³, ¹RHEUMATOLOGY, RUSH UNIVERSITY, CHICAGO, IL, ²Rush University Medical Center, Chicago, IL, ³Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Hepatitis B & C viral infections are widely prevalent and the potential of immunosuppressive medications (ISM) to exacerbate an underlying viral infection is well…
Abstract Number: 1841 • 2015 ACR/ARHP Annual Meeting
Meningitis in Systemic Lupus Erythematosus Patients: Epidemiologic Profile of Listeria Monocytogenes Infection. a Single-Center Study
Ana Barrera-Vargas¹, Javier Merayo-Chalico², Armelle Pérez Cortés Villalobos³, Alfredo Ponce de León³, Jorge Alcocer-Varela¹ and Diana Gómez-Martín¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Infectology and Microbiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Infections are an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. These patients are more prone to develop infections, both…
Abstract Number: 1842 • 2015 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus and Chikungunya Fever: Interactions during the 2014 Outbreak in Martinique
Bastien Bigeard¹, Katlyne Polomat², Emilie Javelle³, Serge ARFI², Lauren Brunier-Agot⁴, Florence MOINET², Fatiha Najioullah⁵, Elodie Curlier⁶, Andre Cabié⁷, Michel DeBandt¹, Georges Jean Baptiste² and Christophe Deligny², ¹internal medicine and rheumatology, Zobda Quitman Hospital, Fort de France, Martinique, ²Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, ³Tropical and Infectious Diseases, Laveran Military Teaching Hospital, Marseille, France, ⁴Internal medicine and rheumatology, Zobda Quitman Hospital, Fort de France, Martinique, ⁵virology, Zobda Quitman Hospital, Fort de France, Martinique, ⁶infectiology, dermatology and internal medicine, CHU de Guadeloupe, Pointe à Pitre, Guadeloupe, ⁷infectious disease, Zobda Quitman Hospital, Fort de France, Martinique
Background/Purpose: There is no data in the literature about chikungunya fever (chik) and SLE. Martinique (French West Indies) experienced for the first time an outbreak…
Abstract Number: 1843 • 2015 ACR/ARHP Annual Meeting
Bloodstream Infections in Systemic Lupus Erythematosus Patients Are Associated with Severe Lupus Flares
José Jiram Torres Ruiz¹, Ana Barrera-Vargas², Rigoberto Ortíz-Hernández², Jorge Alcocer-Varela² and Diana Gómez-Martín², ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Infections are an important cause of mortality and morbidity in systemic lupus erythematosus (SLE) patients. Bloodstream infections (BI), which are especially severe and relatively…
Abstract Number: 1844 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Complicated Pneumonia in Systemic Lupus Erythematosus (SLE)
Gabriela García-Guevara¹, Ricardo Ríos-Corzo², Juan Ávila-Vázquez³, John Hernández-Flores⁴, Eduardo Carrillo-Maravilla⁵, Juan Jakez-Ocampo⁶, Hilda Fragoso-Loyo⁷, Luis Llorente⁸ and Yemil Atisha-Fregoso⁹, ¹Vasco de Quiroga #15, Tlalpan, Belisario Domínguez Sección XVI, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²Escuela de Medicina, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico, ³Escuela Nacional de Medicina, Instituto Tecnológico y de Estudios Superiores de Monterrey, Mexico, Mexico, ⁴Escuela de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ⁵Medicina Interna, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, ⁷Vasco de Quiroga 15 Col Seccio, INNCMSZ-Departamento de Inmunología y Reumato, Mexico, Mexico, ⁸Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Pneumonia, remains as a main cause of mortality in patients with SLE. In patients without autoimmune disease, scores as Pneumonia Severity Index (PSI) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].